Rethinking restless legs syndrome treatment: the shift beyond dopamine agonists

Diego Garcia-Borreguero, MD, PhD, Sleep Research Institute, Madrid, Spain, discusses evolving treatment strategies for restless legs syndrome (RLS). He reviews the growing role of gabapentinoids as first-line therapy, explains concerns surrounding long-term dopamine agonist use, and highlights important considerations for monitoring safety and cognitive function during treatment. This interview took place at the 40th annual meeting of the Associated Professional Sleep Societies (APSS) in Baltimore, MD. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.